Date Posted
This hybrid NASEM MCD workshop will examine the state of the science for clinical use of multi-cancer detection (MCD) tests. The NCI Division of Cancer Prevention staff will present on Monday, October 28. Videos of the speaker presentations and speaker slides are available in the “About” section of the NASEM MCD Workshop homepage.
Session 1: Overview of Multicancer Detection Testing (1 hour, 45 minutes)
Keynote Presentation: How Much Do You Want to Know? The Peril and Promise of an MCD-Driven Future (9:00-9:20 a.m.)
W. Kimryn Rathmell, M.D., Ph.D., M.M.H.C., Director, National Cancer Institute (NCI)
Panel Discussion on How Multicancer Detection Testing Works (9:50-10:45 a.m.)
Panelist: Christos Patriotis, Ph.D., Program Officer, Division of Cancer Prevention (DCP), NCI
Clinical Trials for Evaluating the Mortality Benefits of MCD Testing (11:10-11:20 a.m.)
Hormuzd Katki, Ph.D., Senior Investigator, Division of Epidemiology and Genetics, NCI
Session 2: MCD Test Validation (1 hour, 30 minutes)
Panel Discussion on MCD Test Validation (10:40-11:35 a.m.)
Panelist: Philip Castle, Ph.D., M.P.H., Director, Division of Cancer Prevention (DCP), NCI
Session 3: Examples of MCD Tests in Development and Clinical Use (1 hour, 20 minutes)
Co-Moderator: Philip Castle, Ph.D., M.P.H., Director, DCP, NCI
Overview of MCD Tests in Development and Clinical Practice (1:30-1:45 p.m.)
Wendy Rubinstein, M.D., Ph.D., Senior Scientific Officer, DCP, NCI